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Abstract
Background: Inherited retinal degenerations (IRDs) preferentially affecting cone photoreceptor function are being
considered for treatment trials aiming to improve day vision. The purpose of the current work was to develop
cone-specific visual orientation outcomes that can differentiate day vision improvement in the presence of
retained night vision.
Methods: A lighted wall (1.4 m wide, 2 m high) resembling a beaded curtain was formed with 900 individually
addressable red, blue and green LED triplets placed in 15 vertical strips hanging 0.1 m apart. Under computer
control, different combination of colors and intensities were used to produce the appearance of a door on the wall.
Scotopically-matched trials were designed to be perceptible to the cone-, but not rod-, photoreceptor based visual
systems. Unmatched control trials were interleaved at each luminance level to determine the existence of any
vision available for orientation. Testing started with dark-adapted eyes and a scene luminance attenuated 8 log
units from the maximum attainable, and continued with progressively increasing levels of luminance. Testing was
performed with a three-alternative forced choice method in healthy subjects and patients with Leber congenital
amaurosis (LCA) caused by mutations in GUCY2D, the gene that encodes retinal guanylate cyclase-1.
Results: Normal subjects could perform the orientation task using cone vision at 5 log attenuation and brighter
luminance levels. Most GUCY2D-LCA patients failed to perform the orientation task with scotopically-matched test
trials at any luminance level even though they were able to perform correctly with unmatched control trials. These
results were consistent with a lack of cone system vision and use of the rod system under ambient conditions
normally associated with cone system activity. Two GUCY2D-LCA patients demonstrated remnant cone vision but
at a luminance level 2 log brighter than normal.
Conclusions: The newly developed device can probe the existence or emergence of cone-based vision in patients
for an orientation task involving the identification of a door on the wall under free-viewing conditions. This key
advance represents progress toward developing an appropriate outcome measure for a clinical trial to treat
currently incurable eye diseases severely affecting cone vision despite retained rod vision.
Keywords: Inherited retinal degenerations, Achromatopsia, Cone dystrophy, Cone-rod dystrophy, Blue-cone
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Background
Inherited retinal degenerations (IRD) are a molecularly
heterogenous group of diseases that cause vision loss [1].
IRDs remain currently incurable but preclinical studies
have been generating dozens of potential treatment ave-
nues which are slowly moving to clinical trials [2]. The
ultimate proof of value of any treatment must come from
rigorously-conducted clinical trials that have chosen ap-
propriate outcome measures to determine whether the
treatment is not only safe but also efficacious. Vision out-
comes used in clinical trials generally fall into two categor-
ies. First category of vision outcomes are designed to
detect slowing of progression of disease. Examples of such
outcomes include use of visual acuity, visual field and
electroretinogram testing over many years in clinical trials
of nutritional supplements [3, 4]. The second category of
vision outcomes are designed to detect an improvement
of vision occurring over a relatively short period following
treatment. Examples of such outcomes include use of psy-
chophysical methods to determine major increases in day
and night vision following gene therapy [5, 6]. Usefulness
of such improvements of vision to patients’ daily lives can
be evaluated with mobility tests under carefully controlled
laboratory conditions [7, 8].
Cone photoreceptor diseases (CPDs) are a subset of
IRDs that preferentially affect day vision by causing im-
paired clarity of vision, abnormal color vision, unstable
fixation, and reduced extent of visual fields; rod photo-
receptor based night vision is either normal or relatively
better preserved than day vision. CPDs include progres-
sive cone and cone-rod dystrophies, and cone dysfunction
syndromes that are classically described as stationary
[9, 10]. The vision in CPDs is often seriously compro-
mised by photoaversion, the high sensitivity to and dis-
comfort from daytime ambient light levels [11]. Well
known CPDs include achromatopsias caused by CNGA3,
CNGB3, GNAT2, PDE6C and PDE6H gene mutations
[12], blue-cone monochromacy caused by cone pigment
mutations [13, 14], and cone-rod dystrophies caused by
ABCA4 mutations [15]. Less well known is the combin-
ation of CPD and congenital ultra-low vision that occurs
in Leber congenital amaurosis (LCA) caused by GUCY2D
mutations [16, 17]. Promising preclinical studies suggest
GUCY2D-LCA could be treatable by gene therapy in
order to improve the cone function [18, 19]. Efficacy out-
come measures in clinical trials involving CPDs will likely
include visual acuity, color vision, and fixation in order to
detect improvements driven by cone vision as opposed to
light-adapted rod vision. Also important would be orienta-
tion and mobility tests to determine the usefulness of cone
vision improvements detected; the latter is especially im-
portant in the GUCY2D-LCA population with low vision.
We have previously published mobility performance met-
rics quantifying the ability of LCA patients to move
through an indoor obstacle course at different ambient
room illumination conditions [7]. It may be argued that a
version of the same test limiting the conditions to the
brightest illuminations could be applied to CPDs in order
to measure day vision. However, our recent psychophysical
studies have revealed that CPD patients adapt to their
visual disability by using rod-based night vision function to
accomplish many tasks that are normally performed with
cone-based day vision [11, 14, 17]. Using mobility tasks in
brighter ambient lights would not be helpful since CPD
patients tend to squint to limit light-adaptation to their rod
function. Here we describe a different strategy for evaluat-
ing cone-based vision for orientation in CPDs using a
chromatic pseudo-natural scene in a controlled laboratory
environment under free viewing conditions.
Methods
Subjects and clinical data
Patients (n= 7) with GUCY2D-LCA (Table 1) and subjects
with healthy vision (n= 8) participated in this study.
GUCY2D-LCA patients enrolled in the current study were
different than those included in our previous publication
[17]. All subjects had complete clinical ocular examinations,
including best-corrected visual acuity. The tenets of the
Declaration of Helsinki were followed, and informed consent
and assent were obtained from all patients. The research was
approved by the institutional review board at the University
of Pennsylvania.








1 F 7 Ser448X Ser448X RE HM +3.25
LE 20/800 +3.25
2 M 9 Arg768Trp Arg768Trp REb NLP UP
LEb NLP +6.00
3 F 11 Arg768Trp Glu840 ins6bp RE 20/250 −0.25
LE 20/250 −2.00
4 M 12 Arg588Trp Thr839 del1bp RE 20/125 +2.75
LE 20/125 +1.00
5 F 14 Arg768Trp −146 T>C RE 20/250 −2.50
LE 20/400 −3.50
6 F 14 Gln156X Ser819 del1bp RE LP +5.00
LEb LP UP
7 F 59 Thr312Met Arg795Trp RE 20/400 −0.50
LE 20/400 −2.00
F female, M male, RE right eye, LE left eye, LP light perception, HM hand
motion, NLP no light perception, UP unable to be performed
aSpherical equivalent
bCataract
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Orientation device: discrimination of door on wall by rods
and cones
Fifteen tricolor LED strips (Neopixel RGB-PID1460,
Adafruit Industries, NY) were hung with 0.1 m lateral
separation to result in a vertical plane resembling a wall
that is 1.4 m wide by 2 m high. The device subtends 34°
horizontally and 48° vertically when observed from the
test distance of 2 m. The LED strips were left free to
flow vertically permitting traversal in a way similar to
walking through a beaded curtain (Fig. 1a, left). The
direction of the maximum emission of the LEDs was
kept perpendicular to the plane by the montage to as-
sure uniformity of light output across strips. Each vertical
segment contained 60 triplets of individually addressable
red, green and blue LEDs with peak wavelengths of 630,
518 and 460 nm, and FWHM of 14, 34 and 22 nm,
respectively (Fig. 1a, upper right). LED spectra were mea-
sured with a spectrometer calibrated with a wavelength
scale reference (USB2000 and Hg-1, Ocean Optics,
Dunedin, FL). Each individual LED was controlled by a
dedicated constant-current driver (WS2812B, WorldSemi,
China) with 8-bit pulse-width-modulation (PWM) resolu-
tion permitting electronic luminance adjustment over a
2.41 log unit range. All strips were controlled using a
single microcontroller (Arduino Mega, Ivrea, Italy) with
an USB connection to a PC. Custom software was written
for both the microcontroller (Wiring) and the PC applica-
tion (Java, Linux). The device was programmed to pro-
duce a rectangular pattern target, 3-strip wide, defining
the “door”, surrounded by the rest of the strips defining
the “wall”. Two color combinations were used: green door
on a blue wall (Fig. 1a, left), and a green door on a red wall
(not shown). The perception of the door on the wall
would be expected to depend on the luminance of each
color and luminance difference between the colors. Also
contributing to the perception are the adaptation state of
the subject and the availability of functioning photorecep-
tor populations in the retina. For the main test trials, the
intensities of the two lights used in each combination were
chosen to be scotopically-matched and produced the same
relative effectiveness for the rod-photoreceptor based vi-
sion. Due to the differences in the spectral sensitivity
curves between scotopic and photopic systems, the
scotopic-match would result in mismatched effectiveness
for photopic cone-photoreceptor based vision (Fig. 1a,
lower right). Specifically, scotopically matched combina-
tions of blue/green and green/red produce a luminance
contrast for cones of 0.8 and 2.5 log units, respectively
(Fig. 1a, lower right). The scotopic matches were prelimin-
arily determined using a radiometer calibrated for scotopic
luminance (IL1700 with ZCIE filter, International Light,
Peabody, Massachusetts) and the matches were fine-tuned
near the normal rod absolute threshold based on results
from dark-adapted normal observers using the final device
implementation. Based on previous dark-adapted sensitiv-
ities obtained with two-color methods [17], we assumed
scotopic matching in GUCY2D-LCA to be similar to
normal subjects.
A three alternative forced-choice (3-AFC) experimen-
tal design was implemented by presenting the “door” at
three locations (left, center or right) on the “wall”
(Fig. 1b). The percent correct door position identifica-
tion was estimated by conducting a set of at least ten tri-
als, and required n ≥ 7 correct determinations to reject
the null hypothesis of no discrimination at the α = 0.05
level, yielding a power of 88 %. Several sets of trials were
performed sequentially to determine the percent correct
as a function of scene luminance. Specifically, experi-
ments started with fully-dark-adapted subjects and a
very dim scene luminance, in which perception is rod-
mediated in normal subjects, and it was increased until
the dynamic range limit of the device was reached. The
relative door/wall intensities were kept scotopically
matched at all scene luminances. As full mobility course
traversals for this number of trials would become pro-
hibitive, we divided the assessment into two stages. A
first stage was designed to determine the orientation
capacity of subjects, and to obtain the contributions of
rod and cone photoreceptor systems towards orientation
capacity. The orientation sessions reported in the
current work consisted of verbal assessments of the door
location on the wall while the patient is located at the
start of the course. The trials could proceed rapidly and
total session durations were kept below 30 min. A sec-
ond stage designed to obtain mobility-specific metrics
and consisting of active course traversals may be devel-
oped in the future as treatment initiatives become avail-
able. Such a second mobility stage would piggyback on
the orientation stage reported here by using a carefully
selected subset of scene luminance parameters appropri-
ate to each subjects’ level of vision. Also, the test paradigm
is flexible enough to be adapted for use in the future in
CPDs that differ in the relative losses of each cone sub-
system, or in treatment approaches that may target prefer-
entially one of the cone classes.
Detailed methodology to determine orientation capacity
Each dark-adapted (>45 min.) subject is placed at the
start of the course wearing a pair of goggles fitted with
neutral density filters (Roscolux R98, Rosco Laboratories,
Sun valley, CA). The goggles are used to adjust the scene
luminance over a greater dynamic range than possible
electronically, and do not interfere with the scene bound-
aries when looking straight ahead. The different levels of
scene luminance are obtained by varying the number of
neutral density filter sheets in the goggles. As the spectral
absorbance of the individual sheets is not perfectly flat,
the combined spectral characteristic of the stack of filters
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Fig. 1 (See legend on next page.)
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changes slightly as more sheets are added. To compen-
sate for this effect, the resulting light output of the
combination of device plus filter stack is kept scotopi-
cally matched at all times by small electronic adjust-
ments of the LED PWM level.
A set of trials consists of no less than 10 scotopically-
matched test trials plus a number of scotopically- and
photopically-unmatched control trials (Fig. 1c, left). One
of these sets is performed for each scene luminance,
proceeding from dim to bright. The unmatched trials
are used for control (should produce a success fraction
close to 100 % for subjects having any form of orienta-
tion vision at the tested scene luminance) and to main-
tain orientation during the trials, and also to explain the
test to subjects with very low vision. The contrast level
for the control trials greatly exceeds the range of sco-
topic matches in normal subjects, which is approxi-
mately 0.4 log wide (Fig. 1d). Matched and mismatched
trials are randomly interleaved by the software, with
control (unmatched) trials being 20 % of the total trials
on average. For each trial, a sound is produced after the
adjustment of the wall and door intensities by the com-
puter, and the subject is asked to verbally report the
apparent door position as “Left”, “Center” or “Right”;
they are encouraged to guess one of the three choices if
unable to determine where the door is. The responses
are recorded by the computer. Figure 1e illustrates
representative examples of three sets producing differ-
ent success rates (33, 50 and 100 %) for test trials
(filled circles) with instances of interleaving control
trial sequences (open triangles). Failure to discrimin-
ate the door position is signaled by a yield of ideally
33 % of correct answers to the 3-AFC design. Full
discrimination implies near 100 % answers being cor-
rect. Results are acquired under free viewing condi-
tions, except for illuminations requiring attenuating
goggles.
All normal data were fit with a logistic function of the
form
p ¼ γ þ 1−γ−λð Þ
1þ e − x−θð Þσð Þ
 
where p is the probability of correct, x is the scene lumi-
nance, γ is guessing probability (fixed to 0.3) and λ is the
lapsing probability (fixed to 0) [20]. The spread param-
eter, σ, was allowed to vary for normal results but held
constant at the normal value for the patient results. The




The dimmest scene luminance (8 log attenuation from
maximum) used in the current work was well within the
range of normal scotopic vision. With unmatched control
trials, normal subjects reliably (>65 %) saw the location of
the door on the wall but did not report perception of color
(not shown). For the scotopically-matched test trials, door
and wall were unable to be differentiated by normal sub-
jects. The average percent correct (identification success
rate) was within the range of hypothetical probability
given just by chance (mean 33 %; 95 % confidence interval
4 %-63 %; n = 10 trials; binomial), as expected from ran-
dom guessing for a 3-AFC design (Fig. 2a). Similar results
were obtained for a green door on a blue wall, and for a
green door on a red wall. When the scene luminance was
increased by approximately 2 log units (~6 log attenu-
ation) success rate remained near chance (33 %) suggest-
ing the continued lack of visibility by the normal photopic
cone system. Upon a further increase of the scene lumi-
nance by an additional 2 log units (~4 log attenuation),
there was a clear increase in percent correct, indicating
the onset of normal cone vision occurring between 6 and
4 log attenuation with the threshold (θ) being on average
at 5 log attenuation (Fig. 2a). At ~4 log attenuation and
higher levels, subjects also reported the color of the wall
and door for both scotopically-matched test trials and
(See figure on previous page.)
Fig. 1 Presentation of scotopically matched scenes on an LED-lit wall. (a) Left, LED-lit wall and door device used for the three-alternative
forced-choice design. A mix of light intensities for the “door” (three stripes at right, center or left) and “wall” (elsewhere) is calculated to be visible
to cone-based vision but unable to be differentiated with rod-based scotopic vision. Right, spectral content of the LED lights compared to the spectral
sensitivities of the rod (scotopic, V’ʎ) and cone (photopic, Vʎ) vision. All curves are normalized to unity at maximum. The relative intensities of the three
lights are set such that they have the same effectiveness for rods (lower left) but substantially different effectiveness when perceived by cones (lower
right). These differences permit differentiation of door and wall, and enhance visual orientation performance. (b) Rod vision is expected to perceive
the scene as uniform stripes with no features (upper panels), and cone vision is expected to perceive the “door” as green stripes on a blue background
(lower panels). (c) Appearance of unmatched control trials that should be visible to either rod or cone systems. (d) Departures of more
than approximately 1.5 dB (0.15 log) from the scotopically matched mix of lights result in successful door-wall differentiation in normal
subjects. (e) Representative examples of scotopically-matched test trials interleaved with unmatched control trials. For a three-alternative
forced-choice setup, a subject with rod vision but no cone vision would be expected to get 33 % correct for matched-stimuli on average, whereas a
subject using cone vision would be expected to get 100 % correct. Unmatched control presentations with door dimmer (1) or brighter (2) than wall
are used to determine whether the subject has any vision (rod or cone or both) under the testing conditions
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unmatched control trials. This perceptual behavior contin-
ued through the maximum available scene luminance of 0
log attenuation (Fig. 2a).
GUCY2D-LCA patients with no evidence of cone function
We first considered a subset of four GUCY2D-LCA pa-
tients (P1, P3, P6, and P7) with visual acuities ranging
Fig. 2 Identification of cone vision as a function of scene luminance. (a) Percent correct identification of the location of photopically-mismatched
but scotopically-matched trials using a three-alternative forced-choice method in normals as a function of scene luminance. Near normal scotopic
threshold (7–8 log attenuation), subjects cannot differentiate between door and wall any better than chance. Upon increase in scene luminance,
colors become visible and door identification accuracy reaches 100 %. The sigmoidal curve is a logistic function fitted to the data, with parameters
θ = −5.01 log (threshold) and σ = 0.28 log (spread). (b) Five GUCY2D-LCA patients that fail to perform the visual orientation task with scotopically-
matched trials across the full 8 log unit dynamic range of scene luminances (symbols). Four of the patients successfully orient with unmatched control
trials (upper gray bars) over a range of scene luminances suggesting their use of scotopic vision. (c) Two GUCY2D-LCA patients who can
correctly perform visual orientation task with scotopically-matched and unmatched trials but require greater scene luminance than normal.
Fitted function and parameters as in (A) except for the shifted threshold parameter, which resulted in θ = −3.3 log. Both green/blue and
green/red data are shown
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from light perception (LP) to 20/250 (Table 1). With the
newly developed orientation task, P1 and P3 had no dif-
ficulty correctly identifying the location of the door on
the wall during unmatched control trials performed with
dim scene luminances between 8 and 6 log attenuation
(Fig. 2b, upper gray bars). These results were consistent
with their relatively retained rod vision determined psy-
chophysically. Throughout the rest of the brighter scene
luminances, these two patients continued to correctly
identify the location of the door on unmatched control
trials (Fig. 2b, upper gray bars) but performed no differ-
ent than pure guessing for the scotopically-matched test
trials (Fig. 2b, symbols). P6 and P7 required higher scene
luminances, approximately 5 and 2 log attenuation,
respectively, in order to correctly identify the location of
the door during unmatched control trials (Fig. 2b, upper
gray bars). Again throughout the rest of the brighter
scene luminances, P6 and P7 performed correctly on un-
matched control trials but not on scotopically-matched
test trials (Fig. 2b, symbols). The results P1, P3, P6 and
P7 were consistent with no cone-based vision being used
for the orientation task and retained rod-based vision
functioning adequately for orientation even under bright
scene luminance conditions [17]. Last to be considered
was P2 who could not perceive any light and he was in-
cluded for method validation. Appropriate for the lack
of light perception, P2’s orientation results were no dif-
ferent than guessing for both unmatched control and
scotopically-matched test trials. His results were consist-
ent with lack of rod- and cone-based vision over the full
8 log unit dynamic range tested.
GUCY2D-LCA1 patients with detectable but abnormal
cone function
Next we considered two GUCY2D-LCA patients (P4 and
P5) in whom visual acuities ranged from 20/125 to 20/
400 (Table 1). With unmatched control trials, P5 could
identify the location of the door near 5 log attenuation
and at higher scene luminances (Fig. 2c, upper gray
bars). With scotopically-matched test trials, at approxi-
mately 2 log attenuation P5 could successfully identify
the location with nearly 100 % accuracy. The capacity to
visually orient to both unmatched as well as matched
trials continued to the brightest scene luminance. P4 on
the other hand, did not identify correctly either matched
or unmatched trials throughout the range up to the 2
log attenuation. At that luminance and maximum lumi-
nance, P4 could correctly identify both matched and
unmatched trials. These results suggested a detectable
cone based vision in P4 and P5 with a threshold between
2 and 4 log attenuation (average threshold θ = 3.3 log)
which would correspond to an approximate 2 log eleva-
tion compared to normal cone vision. P5 had better sco-
topic vision compared to P4.
Discussion
Evaluation of the real-world consequences of incremen-
tal improvements achieved by novel treatment strategies
is very challenging in clinical trials of patients with
ultra-low vision. Orientation and mobility (O&M) cap-
acity can be evaluated either by observation of patients
tending to natural tasks in the real-world [21], or meas-
urement of their performance in courses built within
controlled environments under standardized conditions
that simulate some aspects of the real-world [7, 8, 22],
or in virtual reality environments [23, 24]. In the current
context, orientation can be defined as a process by
which position is established using visual cues with re-
spect to features and obstacles within the environment;
non-visual orientation, such as use of echolocation [25]
is excluded. Mobility, on the other hand, is defined as
the capacity of the subject to use the mental map of the
environment created by a preceding orientation step to
reach a pre-specified feature avoiding any obstacles that
may be on the path [26]. Thus evaluation of orientation
can be thought of as a prerequisite to the evaluation of
vision-based mobility performance (as opposed to non-
visual assistive tools such as a cane). O&M performance
strongly depends on visual field extent, scotoma loca-
tion, and visual acuity [27–29]. One of the important
considerations for O&M evaluation is the control of
ambient light environment and the apparent contrast of
features therein [30]. For example, RPE65-LCA patients
behave like sighted individuals in a brightly lit mobility
course but behave as severely visually impaired in a dim
light environment [7].
GUCY2D-LCA is one of the more common molecular
causes of LCA and involves the phototransduction path-
way of both rod and cone photoreceptors [17, 31–33].
There is usually severe vision loss with low visual acuity
and profound photoreceptor dysfunction by retinal elec-
trophysiology [16, 17, 32]. GUCY2D-LCA is unlike any
other IRD described to date because it invariably dem-
onstrates a retinal laminar structure that is near normal
and completely dissociated from the extremely severe
visual impairment experienced by the patients. Using
full-field psychophysical methods, cone sensitivity losses
tend to be much greater than rod sensitivity losses [17]
making GUCY2D-LCA a form of CPD often associated
with congenital ultra-low vision.
As a first step in evaluating O&M performance in
GUCY2D-LCA patients, we designed and built an orien-
tation device consisting of a “door” on a “wall”. We used
chromatic contrast as a visual cue in order to avoid use
of the rod-photoreceptor based night vision of patients
for day vision tasks such as it occurs in other CPD
patients [11, 14]. Previous investigators have stressed
the importance of using relatively short sessions on a sim-
ple course design of reduced dimensions and repeated
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measurements to assess severely affected patients in a rea-
sonable time [34]. It was concluded that learning effects
are unlikely to confound assessment in those conditions.
We pursued similar goals by utilizing a device with a rea-
sonably wide coverage of field of view under free viewing
conditions and a rapid way of obtaining replications by
using the patient’s verbally reported door localization
information.
Conclusions
Novel treatment trials such as gene augmentation therapy
are in the planning stages for CPDs. Here we developed a
device and a technique which can be used as an outcome
measure to evaluate the cone-vision-based orientation
capacity of CPD patients undergoing treatment trials.
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